Lv1
50 积分 2025-09-02 加入
The efficacy and safety of keverprazan, a novel potassium‐competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double‐blind multicentre study
15小时前
已完结
Evidence‐based traditional Chinese medicine research: Two decades of development, its impact, and breakthrough
1天前
已完结
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
9天前
已完结
Nivolumab dans le traitement des CBNPC
12天前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
12天前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
13天前
已完结
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
15天前
已完结
The self‐evaluation of upper‐gastrointestinal symptoms in Chinese patients with digestive disease: A multicenter questionnaire survey
15天前
已完结
Comparative Effectiveness of First-Line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors According to IMDC Risk Groups in Metastatic Renal Cell Carcinoma: A Meta-Analysis
16天前
已完结
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
19天前
已完结
皖公网安备34019202002308
